Stock Details
ABBV is AbbVie Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 157.28$. Average daily volumn in 3 months 7.34M. Market cap 267.51B

Stock symbol : ABBV. Exchange : NYSE. Currency : USD
Lastest price : 150.00$. Total volume : 8.25M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

AbbVie Inc. (ABBV)
Last Price

Previous Close150.57
Day Range147.75-150.05
Bid150.00 x 800
Ask155.00 x 1k
Average Volume7.34M
Market Cap267.51B
52 Week Range105.56-175.91
Trailing P/E21.52
Foward P/E12.50
Dividend (Yield %)3.75%
Ex-Dividend Date2022-04-14

Financial Details

According to AbbVie Inc.'s financial reports the company's revenue in 2021 were 56.2B an increase( +24.44%) over the years 2020 revenue that were of 45.8B. In 2021 the company's total earnings were 11.54B while total earnings in 2020 were 4.62B( +175%).

Loading ...


AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behรงet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCL... EXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Market Cap:
Total Assets:
Total Cash:

News about "AbbVie Inc."


What Kind Of Shareholders Hold The Majority In AbbVie Inc.'s (NYSE:ABBV) Shares?

Source from : YAHOO!Finance - 1 days ago

If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its ...See details»

ABBVIE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of AbbVie Inc. - A

Source from : ์•„ํฌ๋กœํŒฌ - 17 hours ago

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (โ€œKSFโ€), announces that KSF has commenced an investigation into AbbVie Inc. (NYSE: ...See details»


AbbVie's Correction Appears to Be Over: Here's Where the Stock Could Be Headed

Source from : - 2 days ago

Recently, ABBV pulled back from an April high but the correction is showing signs it is over. Should you be a buyer? Let's check the charts. In the daily bar chart of ABBV, below, we can see that the ...See details»

Here is what you need to look for: AbbVie Inc. (ABBV)

Source from : investchronicle - 4 days ago

AbbVie Inc. (ABBV) is priced at $148.03 after the most recent trading session. At the very opening of the session, the stock price was $151.65 and reached a high price of $152.00, prior to closing the ...See details»


AbbVie Inc. Investors: Last Days to Actively Participate in the Class Action Lawsuit; Portnoy Law Firm

Source from : FOX8 Cleveland - 2 days ago

The Portnoy Law Firm advises AbbVie Inc. (โ€œAbbVieโ€ or the โ€œCompanyโ€) (NYSE: ABBV) investors that a class action filed on behalf of investors that purchased Celsius shares between April 30, 2021 and ...See details»

ABBV LAWSUIT ALERT: Levi & Korsinsky Notifies AbbVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Source from : FOX31 Denver - 2 days ago

ABBVย investors may also contact Joseph E. Levi, Esq. via email atย [email protected]ย or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false ...See details»

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AbbVie Inc. - ABBV

Source from : Associated Press - 3 days ago

Pomerantz LLP is investigating claims on behalf of investors of AbbVie Inc. (โ€œAbbVieโ€ or the โ€œCompanyโ€) (NYSE: ABBV). Such inves ...See details»

AbbVie Inc.: Reaffirming BUY with target of $165

Source from : YAHOO!Finance - 3 days ago

Find the latest AbbVie Inc. (ABBV) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance ...See details»

AbbVie Inc. (NYSE:ABBV) Vice Chairman Michael Severino Sells 100,000 Shares

Source from : ETF Daily News - 17 days ago

AbbVie Inc. has a fifty-two week low of $105.56 and a fifty-two week high of $175.91. The company has a 50-day simple moving average of $157.51 and a 200-day simple moving average of $139.45.See details»

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

Source from : Nasdaq - 23 days ago

AbbVie (ABBV) is one of the stocks most watched ... of the author and do not necessarily reflect those of Nasdaq, Inc. Zacks is the leading investment research firm focusing on stock research ...See details»

AbbVie Inc. (NYSE:ABBV) Given Consensus Rating of โ€œBuyโ€ by Analysts

Source from : ETF Daily News - 15 days ago

AbbVie Inc. (NYSE:ABBV โ€“ Get Rating) has received a consensus recommendation of โ€œBuyโ€ from the nineteen brokerages that are covering the company, Marketbeat Ratings reports. Five research ...See details»

ABBV LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving AbbVie Inc.

Source from : Barron's - 4 days ago

The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased AbbVie Inc. ("AbbVie") (NYSE: ABBV) between April 30, 2021 and August 31, ...See details»

AbbVie: Q1 2022 Results Dampen Enthusiasm And Test Management's Growth Plans

Source from : Seeking Alpha - 28 days ago

Yesterday after market close, AbbVie Inc. (NYSE:ABBV) - currently the U.S.' third-largest pharmaceutical company by market cap, behind only Johnson & Johnson (JNJ) and Pfizer (PFE), announced its ...See details»

AbbVie Inc. (ABBV) Reports First-Quarter 2022 Financial Results

Source from : MarketWatch - 29 days ago

AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2022. โ€œThis year is off to a strong start. Our first quarter results highlight the diversity of our portfolio ...See details»